Evolving Therapies in Clinical Practice in IBD

April 29 – 30, 2016
Hilton Prague
Prague, Czech Republic

Program
12 credit hours (CME) have been awarded for the Symposium 202 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Dear colleagues,
Dear IBD friends,

It is our great pleasure to cordially invite you to the Symposium 202 to be held in Prague, Czech Republic in April, 2016. There is no doubt that the therapy of IBD has evolved substantially since the last Falk Symposium in Prague thirteen years ago, and this progress continues. The upcoming symposium “Evolving Therapies in Clinical Practice in IBD” will focus on several aspects of current IBD management. Introduction of new, pathophysiology-based therapies, discussion on unmet needs, presentation of promising experimental methods as well as improvements in currently used therapeutic modalities all comprise the core of the program. Moreover, you will also have great opportunities to discuss challenging cases requiring a multidisciplinary approach and close cooperation between IBD specialists.

We believe that the outstanding faculty of this Symposium, together with both the renowned organization by the Falk Foundation and the famous spirit of the Czech capital will entice many colleagues to accept this invitation. At the same time, we would like to express our gratitude to Mrs. Ursula Falk and the Falk Foundation for giving us the opportunity to organize this highly prestigious meeting.

On behalf of the scientific organizers,

Prof. Dr. Milan Lukas, Prague
Evolving Therapies in Clinical Practice in IBD

April 29 – 30, 2016
Hilton Prague
Prague, Czech Republic

Registration:
Thursday, April 28, 2016
16.00 – 21.00 h
at the congress office

Scientific Organization:
M. Bortlik, Prague (Czech Republic)
W. Kruis, Cologne (Germany)
M. Lukas, Prague (Czech Republic)
E. F. Stange, Stuttgart (Germany)

Congress Venue:
Hilton Prague
Pobrezni 1
18600 Prague 8
Czech Republic

Information:
Prof. Dr. Milan Lukas
Clinical and Research Center for IBD
Isicare I.V.F. a.s., Lighthouse
Jankovcova 1569/2c
170 04 Prague
Czech Republic
Telephone: +420 234 770 299
Telefax: +420 234 770 300
E-Mail: milan.lukas@email.cz

Official Language:
English

Posters:
A poster session will take place.
For details see page 11.
Friday, April 29, 2016

8.30 Welcome and introduction E. F. Stange, Stuttgart
8.40 Progress in our understanding of IBD M. Lukas, Prague

Session I
Novel therapeutic approaches in medical therapy
Chair: M. Lukas, Prague; E. F. Stange, Stuttgart

9.00 Anticytokine strategy beyond the anti-TNF-alpha therapy – Pathophysiology and clinical implication G. Rogler, Zurich
10.00 Improvement of “leaky” intestinal barrier E. F. Stange, Stuttgart

10.30 Coffee break with poster session

Session II
Unmet therapeutic needs: Focus on intestinal fibrosis
Chair: W. Kruis, Cologne; B. E. Sands, New York

11.00 Pathogenesis of intestinal fibrosis in IBD and perspectives for therapeutic implication F. Rieder, Cleveland
11.30 Do we have a reliable marker of intestinal fibrosis in clinical practice? The role of biochemical markers and imaging methods P. D. R. Higgins, Ann Arbor
12.00 Surgical approach: Resection, strictureplasty and others Y. Panis, Paris
12.30 Lunch break with poster session
Friday, April 29, 2016

Session III
Interactive Session: How to improve our care in IBD?

Chair: M. Bortlik, Prague; Z. Zelinkova, Bratislava

13.30 Case report: Perianal Crohn’s disease requiring complex management
   What should be done in perianal CD?
   Surgeon’s statement
   P. L. Lakatos, Budapest
   Z. Serclova, Prague

14.00 Case report: Acute severe ulcerative colitis
   What should be done in patients with acute severe UC?
   Is there a role for second rescue therapy or is surgery required?
   A. E. Dorofeyev, Kiev
   M. Martí Gallostra, Barcelona

14.30 Case report: Immunosuppressive therapy in patients with IBD and malignancy
   What should be done in IBD patients with prior malignancy?
   G. Novacek, Vienna
   J. Cosnes, Paris

15.00 Coffee break with poster session

Session IV
How to best use the drugs?

Chair: M. Ferrante, Leuven; P. L. Lakatos, Budapest

15.30 Impact of perioperative medical therapy on surgical outcome
   A. Dignass, Frankfurt

16.00 Promise and danger of combination therapy
   W. Kruis, Cologne

16.30 Relevance of drug levels and antibodies in clinical practice
   A. Gils, Leuven
Friday, April 29, 2016

Special Lecture

Chair: G. Novacek, Vienna

17.00  What can we learn from epidemiological studies in IBD?  D. Duricova, Prague

17.30  End of afternoon session
Saturday, April 30, 2016

Session V
Biosimilars in clinical practice

Chair: T. Hlavaty, Bratislava; B. Moum, Oslo

9.00 State-of-the-Art Lecture: Does introduction of biosimilars change our understanding of track treatment? B. Moum, Oslo

Early results: Focus on European experience

9.20 Experience with biosimilar infliximab (Remsima®) in Norway J. Jahnsen, Nordbyhagen

9.45 Biosimilar infliximab interchangeability in clinical practice in the Czech Republic M. Lukas, Prague

10.10 Immunogenicity and side effects of biosimilar infliximab treatment in Hungary P. L. Lakatos, Budapest

10.35 Coffee break with poster session

Session VI
Transplantation procedures in the therapy of IBD

Chair: C. J. Hawkey, Nottingham; J. Schölmerich, Frankfurt

11.00 Randomised controlled clinical trial of autologous haemopoietic stem cell transplantation in Crohn’s disease C. J. Hawkey, Nottingham

11.20 Mesenchymal stem cell therapy in Crohn’s disease G. M. Forbes, Perth

11.40 Fecal transplantation W. Reinisch, Hamilton

12.00 Small bowel transplantation P. Drastich, Prague

12.20 Presentation of poster awards E. F. Stange, Stuttgart

12.30 Lunch break with poster session
Saturday, April 30, 2016

Session VII
Challenging clinical cases

Chair: Y. Panis, Paris; E. F. Stange, Stuttgart

13.45 Case reports: May both diseases (CD and UC) exist in one patient?  M. Bortlik, Prague
13.55 Overview: Complications after IPAA  T. Molnár, Szeged
14.20 Case report: Acute flare of ulcerative colitis during pregnancy is still a big problem  M. Protic, Belgrade
14.30 Overview: What should be done in pregnant women with severe UC?  Z. Zelinkova, Bratislava
14.55 Case report: Ileal Crohn’s disease in monozygotic twins  M. Diculescu, Bucharest
15.05 Overview: Limited CD in terminal ileum. Which therapy has to be the first choice?  J. Orhalmi, Hradec Králové
15.30 Coffee break with poster session

Special Lecture

Chair: W. Kruis, Cologne

16.00 Intestinal microbiome: Myths and facts  H. Tlaskalová-Hogenová, Prague
16.30 Conclusions  M. Lukas, Prague
Poster Session

Posters will be exhibited on April 29-30, 2016 in the Hilton Prague. The authors will be in attendance during coffee and lunch breaks on both days.

1. Clinicians’ knowledge about the ionizing radiation of the common investigations used in inflammatory bowel disease
   L. Alrubaiy, S. Al-Rubaye, I. Rikaby, C.L. Ch’ng (Swansea, London, GB)

2. Inflammatory bowel disease in the UK: Is care improving?

3. Evaluation of fecal calprotectin to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) in Qena, Egypt
   M. Alsenbesy, A. Sabra, S. Sayed, M. Kabbash (Qena, EG)

4. Predictive factors for surgery and postoperative complications in patients with chronic inflammatory bowel disease
   S. Ayadi, M. Cheikh, R. Ennaifer, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)

5. Role of the mean platelet volume as a marker of inflammation in Crohn’s disease

6. Mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease

7. Iron deficiency anaemia in inflammatory bowel disease – The psychological, clinical and financial impact of first line intravenous iron therapy
   A.J. Boal, S.I. Squires, G.D. Naismith (Paisley, GB)

8. Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
   C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, G. Lecca, C. Corrado, P. Vernia, P. Paoluzi, E.S. Corazziari (Rome, IT)

9. Digestive strictures complicating Crohn’s disease: Clinical and therapeutic features
   M. Cheikh, I. Ben Aounallah, R. Ennaifer, H. Romdhane, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)

10. Tolerance and efficacy of azathioprine in the treatment of chronic inflammatory bowel disease
    M. Cheikh, S. Ayadi, H. Romdhane, R. Ennaifer, W. Bougassas, H. Ben Nejma, N. Belhadj (Tunis, TN)

11. Clinical outcomes of ulcerative colitis patients treated with 5-aminosalicylates after a first course of corticosteroids
12. Risk factors for colectomy in ulcerative colitis patients with severe flare-up
W. Dahmani, W. Ben Mansour, A. Guedich, M.H. Loghmari, O. Hellara, F. Bdioui,
L. Safer, H. Saffar (Monastir, TN)

13. Cigarette smoke modulates the effect of dextran sulfate sodium (DSS)-induced
colitis on subpopulation of T cells in blood and colon in mice
J. Daniluk, U. Daniluk, M. Rusak, J. Reszec, M. Dabrowska, A. Dabrowski
(Bialystok, PL)

14. Non-invasive markers for diagnosis and determination of the severity of Crohn’s
disease in children – Preliminary study
U. Daniluk, I. Werpauchowska, J. Daniluk, J.M. Lotowska, D.M. Lebewsztejn
(Bialystok, PL)

15. Evaluation of angiogenesis in colorectal cancer associated with ulcerative colitis
(Craiova, RO)

16. Prevalence of articular disorder in patients with inflammatory bowel disease
C.I. Deliu, M.C. Bezna, A. Genunche-Dumitrescu, N. Deliu, D. Negaoe (Craiova, RO)

17. Frequency of adverse skin reactions in patients treated with the anti-TNF therapy
C.I. Deliu, M.C. Bezna, A. Genunche-Dumitrescu, O.M. Diaconu, D. Neagoe
(Craiova, RO)

18. The condition of the intestinal microflora in patients with ulcerative colitis com-
bined with hepatic steatosis
L. Demeshkina, E.V. Zygalo, V. Didenko (Dnipropetrovsk, UA)

19. Ulcerative proctitis patients presenting with minimal rectal bleeding may be
overlooked
A. Demirezer Bolat, H. Koseoglu, O. Tayfur Yurekli, S. Ulutas, F.E. Akin,
N.S. Buyukasik, O. Ersoy (Ankara, TR)

20. Adverse reactions versus benefits of anti-TNF agents in inflammatory bowel
disease
O.M. Diaconu, A.-M. Bedelici, C.I. Deliu, A. Genunche-Dumitrescu (Craiova, RO)

21. The prevalence of extraintestinal manifestations in patients with inflammatory
bowel disease
O.M. Diaconu, C.I. Deliu, A.-M. Bedelici, A. Genunche-Dumitrescu (Craiova, RO)

22. Tumor necrosis factor-α, resistin, leptin and ghrelin in ulcerative colitis
O. El-Segai, H. Elbatae, A. Wageeh, G. Ismail, M. Eldomery (Tanta, Khafr El-Sheikh, EG)

23. Management of intra-abdominal abscesses in Crohn’s disease: A monocentric
Tunisian experience
R. Ennaifer, H. Ayadi, B. Bouchabou, M. Cheikh, H. Romdhane, H. Ben Nejma,
W. Bougassas, N. Belhadj (Tunis, TN)

24. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: A
Tunisian monocentric study
R. Ennaifer, B. Bouchabou, H. Ayadi, H. Romdhane, M. Cheikh, W. Bougassas,
H. Ben Nejma, N. Belhadj (Tunis, TN)
25. Tuberculous versus Crohn’s anal fistula: Diagnostic difficulties in endemic area
   R. Ennaifer, H. Ayadi, B. Bouchabou, M. Cheikh, H. Romdhane, W. Bougassas,
   H. Ben Nejma, N. Belhadj (Tunis, TN)

26. Tuberculosis screening before anti-TNF-α therapy in an endemic country
   R. Ennaifer, B. Bouchabou, H. Ayadi, M. Cheikh, H. Romdhane, W. Bougassas,
   H. Ben Nejma, N. Belhadj (Tunis, TN)

27. Toxicity of thiopurines in patients with inflammatory bowel disease: Frequency
    and risk factors
   M. Fekih, A. Laabidi, L. Kallel, M. Amri, N. Ben Mustapha, J. Boubaker,
   M. Serghini, A. Filali (Tunis, TN)

28. Comparison of severe acute colitis inaugurating inflammatory bowel disease to
    followed IBD complicated by SAC
   M. Fekih, A. Laabidi, L. Kallel, M. Hafi, M. Serghini, N. Ben Mustapha, J. Boubaker,
   A. Filali (Tunis, TN)

29. Can we predict response to cyclosporine as second-line therapy in patients with
    severe acute colitis of inflammatory bowel disease?
   M. Fekih, A. Laabidi, M. Serghini, M. Bejaoui, J. Boubaker, L. Kallel, A. Filali
   (Tunis, TN)

30. Smoking status and response to thiopurines in inflammatory bowel disease patients
    A. Filali, N. Ben Mustapha, L. Kallel, H. Hassine, J. Boubaker, M. Serghini,
    J. Boubaker (Tunis, TN)

31. The role of the innate immune components in predicting the risk of early relapse
    of Crohn’s disease
   A. Galushkin, L. Mamedova, G.N. Tarasova (Rostov-on-Don, RU)

32. Quality of life and late diagnosis of inflammatory bowel disease
    O. Gavrilescu, M. Dranga, I. Popa, M. Palaghia, M.A. Badea, C. Mihai, C. Cijevschi
    Prelipcean (Iasi, RO)

33. Anemia and quality of life in inflammatory bowel disease
    O. Gavrilescu, I. Ungureanu, R. Popa, A. Didita, M. Dranga, C. Mihai, C. Cijevschi
    Prelipcean (Iasi, RO)

34. The distinctive features of the therapy for induction of remission of the moderate
    UC in patients with HBV or HCV infection
    A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea, C.I. Deliu,
    O.M. Diaconu (Craiova, RO)

35. The immunosuppressive therapy in induction of remission of the steroid-refractory
    ulcerative colitis in elderly patients
    A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea, C.I. Deliu
    (Craiova, RO)

36. Metabolic syndrome is also prevalent in inflammatory bowel disease
    O. Gharbi, I. Gheribi, N. Ben Mustapha, A. Laabidi, M. Serghini, L. Kallel,
    M. Fekih, J. Boubaker, A. Filali (Tunis, TN)
37. Mean platelet volume: A predictor of therapeutic response to azathioprine in Crohn’s disease

38. Role of the neuropeptides in ulcerative colitis before treatment and in remission
Z. Gök Sargin, N. Erin, B. Yildirim, Ö. Elpek, E. Alkan (Ankara, Antalya, Burdur, TR)

39. Tissue telomerase activity and plasma basic fibroblast growth factor as markers for early detection of dysplasia in chronic ulcerative colitis patients
H. Hamooda, A. Balaash, S. Ismail, H. Elbatae, M. Eldomery, H. Youssef (Tanta, Khafr El-Sheikh, EG)

40. Extraintestinal manifestations in 112 cases of inflammatory bowel disease: Prevalence, types, predisposing factors
L. Hamzaoui, M. Medhioub, O. Ghannei, H. Sahli, M.M. Azouz (Nabeul, TN)

41. Iatrogenic colorectal Kaposi sarcoma complicating a refractory ulcerative colitis in a human immunodeficiency virus-negative patient
L. Hamzaoui, M. Mahmoudi, M. Bouassida, E. Chelbi, M.M. Azouz (Nabeul, TN)

42. Acute abdomen in Crohn’s disease patients: Comparative study between first diagnosed at surgery and known Crohn’s disease

43. Clinical features of elderly-onset ulcerative colitis

44. Predictive factors of postoperative morbidity and mortality in acute severe colitis

45. The economic burden and prevalence of inflammatory bowel disease (IBD) from 2010 to 2014 in Korea
K. Hyo Jong, L. Chang Kyun, R. Sang Youl (Seoul, KR)

46. The clinical features of patients with newly diagnosed ulcerative colitis (UC) in Korea: A population-based inception cohort study
K. Hyo Jong, L. Chang Kyun (Seoul, KR)

47. Enhanced atherogenesis and altered high-density lipoprotein in patients with Crohn’s disease
D. Janelidze, N. Omanidze (Kiev, UA)

48. Latent TB in IBD patients receiving anti-TNF therapy

49. FXR-mediated induces expression of miR29a3p in colonic epithelial cells: Implications for therapy of inflammatory bowel disease
S.J. Keely, A.M. O’Dwyer (Dublin, IE)
50. Inflammatory bowel disease patients’ group with hepatobiliary manifestation. Results of 5-year experience
N.V. Kharchenko, I. Lopukh, D. Janelidze (Kiev, UA)

51. Management of intra-abdominal collections complicating Crohn’s disease: Experience of a Tunisian center
A. Khsiba, M. Fekih, M. Hafi, I. Ghribi, J. Boubaker, L. Kallel, A. Filali (Tunis, TN)

52. MicroRNA expression in the colonic mucosa of pediatric patients with eosinophilic colitis in comparison with Crohn’s disease
Z. Kiss, N.J. Beres, E. Sziksz, A. Vannay, A. Arato, K.E. Müller, A. Cseh, A.J. Szabo, G. Veres (Budapest, HU)

53. One year experience in treating patients with severe ulcerative colitis with biosimilar (infliximab) – Remsima®
A. Koleva, M. Stamboliyska, I.A. Kotzev, A. Angelov (Varna, BG)

54. Our experience with the application of biosimilar infliximab to IBD patients
M. Konecny (Olomouc, CZ)

55. Significance of serological markers in the disease course of ulcerative colitis

56. Predictive factors for severe Crohn’s disease. Results of a Tunisian survey
M. Labbane, K. Torjmane, S. Zarrourk, Y. Bouteraa, S. Ouerdiane (Bizerta, TN)

57. Natural history of non-severe inflammatory bowel disease at onset
M. Labbane, S. Zarrourk, K. Torjmane, Y. Bouteraa, S. Ouerdiane (Bizerta, TN)

58. High-resolution anorectal manometry in IBD patients: A pilot study
A. Ladic, N. Rustemovic, J. Skunca, S. Cukovic-Cavka (Zagreb, HR)

59. Bile acids regulate intestinal epithelial restitution: Implications for pathogenesis and therapy of IBD
N.K. Lajczak, M.S. Mroz, V. Saint-Criq, S.J. Keely (Dublin, IE)

60. Involvement of PARK7 in the pathomechanism of inflammatory bowel disease

61. Ileal inflammation at the resection margin may be predictive for increased risk of postoperative Crohn’s disease recurrence over a 10 year follow-up

62. Early diagnosis of malignancy of colon polyps
S. Mamatkulov, B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)

63. Determination serum lactoferrin concentration as a way assess treatment of ulcerative colitis
L. Mamedova, G.N. Tarasova, A. Galushkin (Rostov-on-Don, RU)
64. Decreased fibrogenesis in CH25H-/- mice in a newly developed mouse model of intestinal fibrosis  
B. Misselwitz, T. Raselli, A. Wyss, C. Mamie, G. Rogler, M. Hausmann (Zurich, CH)

65. Ulcerative colitis patients with complicated interstitial cystitis  
V. Mokricka, P. Zalizko, J. Pokritnieks, K. Snippe, J. Vilmanis, A. Pukitis (Riga, LV)

66. The choice of treatment the patients with ulcerative colitis  
B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)

67. The problem of the treatment of severe ulcerative colitis  
B.S. Navruzov, S.T. Rakhmanov (Tashkent, UZ)

68. Mucosal healing in ulcerative colitis  

69. New therapeutic approach in ulcerative colitis: Fecal microbiota transplantation  

70. Factors associated with anxiety and depression in Korean IBD patients  
D. Park (Seoul, KR)

71. Comparing the clinical outcomes between young-onset and adult-onset ulcerative colitis: A multicenter KASID study  
D. Park (Seoul, KR)

72. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease  

73. The efficacy and tolerability of azathioprine therapy in inflammatory bowel disease patients  
K. Pavlovska, M. Slaninka Miceska, I. Kikerkov, E. Atanasovska, V. Avramovski, L. Efremovska (Skopje, MK)

74. Extensive pustular pyoderma gangraenosum: The rare skin extraintestinal manifestation of ulcerative colitis. A case report  
C. Pernat Drobez, G. Vujnovic, P.B. Marko (Maribor, SI)

75. Targeting personalized therapies in IBD: Polymorphisms of IL-4 (C-590T) and GJB2 (35delG) genes associate with pro- and anti-inflammatory cytokines  
O.M. Plehutsa, R.I. Sydorchuk, L.P. Sydorchuk, I.I. Sydorchuk, A.R. Sydorchuk (Chernivtsi, UA)

76. Regulatory role of the transcription factor GATA-3 in ulcerative colitis and blocking of experimental colitis by GATA-3-specific DNAzyme  
V. Popp, K. Gerlach, S. Mott, A. Turowska, H. Garn, R. Atreya, I.C. Ho, H. Renz, M.F. Neurath, B. Weigmann (Erlangen, Marburg, DE; Boston, US)

77. Arterial stiffness as a marker of vascular aging in IBD patients – A pilot study  
78. Diagnosis and treatment of Crohn’s disease
S.T. Rakhmanov, B.S. Navruzov (Tashkent, UZ)

79. Can the inflammatory bowel disease biologics registry lead to improved quality of care?
I. Rikaby, L. Alrubaiy, H.A. Hutchesings, J.G. Williams (Cardiff, Swansea, GB)

80. Systematic review of the clinical disease severity indices for inflammatory bowel disease
I. Rikaby, L. Alrubaiy, M. Sageer, H.A. Hutchesings, J.G. Williams (Cardiff, Swansea, GB; Burlington, US)

81. LYC-53976, a ROCK2-selective inhibitor, attenuates the fibrogenic response of intestinal myofibroblasts to TGF-beta and substrate stiffness

82. Factors associated with non-adherence to medication for inflammatory bowel disease: A monocentric Tunisian study

83. Risk factors for decreased bone mineral density in inflammatory bowel disease in a Tunisian cohort

84. Clinical features of the patients with IBD in Coratia
B. Rosic Despalatovic, A. Bratanic, M. Simunic, A. Tonkic (Split, HR)

85. Incidence and severity of pre-pouch ileitis: A distinct disease entity or a manifestation of refractory pouchitis? A retrospective cohort study of patients from Amsterdam, Leuven and London

86. IL-36R signalling in intestinal epithelial cells and fibroblasts promotes mucosal healing in vivo
K. Scheibe, M.F. Neurath, C. Neufert (Erlangen, DE)

87. 5-HT7 receptor mechanism for stress-induced analgesia: A new therapeutic target for inflammatory pain
M. Seyrek, Y.S. Sakin, O. Yesilyurt, M. Leopoldo, A. Dogrul (Ankara, TR; Bari, IT)

88. Extraintestinal manifestations in inflammatory bowel disease (IBD) among Egyptian patients: A tertiary center experience
M. Sharaf-Eldin, M. Enaba, S. Abousaif (Tanta, EG)

89. Thalidomide therapy for vascular malformations of the gastrointestinal tract
S. Surgenor, J. Snook (Poole Dorset, GB)
90. Approaching personalized therapy for IBD: ACE gene’s polymorphisms participate in IBD pathogenesis through changes of colonic microbiota and mesenteric vascularization
A.R. Sydorchuk, T.M. Boychuk, L.P. Sydorchuk, R.I. Sydorchuk, O.M. Plehutsa, I.I. Sydorchuk (Chernivtsi, Kiev, UA)

91. Targeting colonic microbiota in IBD: Oral probiotic therapy
L.P. Sydorchuk, T.M. Boychuk, R.I. Sydorchuk, I.I. Sydorchuk, O.M. Plehutsa, A.R. Sydorchuk (Chernivtsi, UA)

92. Mesalazine vs. probiotic use in maintaining remission in IBD

93. Is it Crohn’s disease (CD) or intestinal TB (iTB), dilemma that can lead to a catastrophe: Case report
Y. Taher, M. Sharaf-Eldin (Tanta, EG)

94. Correlation of MR enterography parameters with clinical and endoscopic disease activity indices

95. The influence of the modified symbiotic bacteria metabolites on immune cells
G. Tereshchuk, D. Vatlitsov (Kiev, UA)

96. 7-alpha-cholestenone and faecal calprotectin in patients with collagenous colitis
R.C. Trimble, D.E. Yung, A. Koulaouzidis (Edinburgh, GB)

97. Hyperbaric oxygen therapy in ulcerative colitis treatment
A. Uzunova-Genova (Sofia, BG)

98. The metabolic deregulation as response on different kind of stress load
D. Vatlitsov, N. Rusetskaya (Kiev, UA)

I.K. Williams, S. Surgenor (Poole Dorset, GB)

100. Adding stewed apricot juice to senna improves the right-side and overall colon cleansing quality for colonoscopy preparation
B. Yasar, E. Abut, H. Kayadibi, F. Akdogan, C. Gonen (Istanbul, Adana, TR)

101. Patients with Crohn’s disease: The hydrogen breath test
E.V. Zygalo, L. Demeshkina, O.V. Sorochan, V. Kudryavtseva (Dnipropetrovsk, UA)
List of Speakers, Moderators and Scientific Organizers

Dr. Martin Bortlik
Clinical and Research Center for IBD
Iscare I.V.F. a.s., Lighthouse Jankovcova 1569/2c
170 04 Prague
Czech Republic
mbortlik@hotmail.com

Prof. Dr. Jacques Cosnes
Service de Gastroentérologie and Nutrition
Hôpital Saint Antoine
184, Rue du Faubourg St.-Antoine
75012 Paris
France
jacques.cosnes@aphp.fr

Dr. Mircea Diculescu
Department of Gastroenterology and Hepatology
Sos. Fundeni 258
022328 Bucharest
Romania
mmdiculescu@yahoo.com

Prof. Dr. Axel Dignass
Medizinische Klinik I AGAPLESION
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info

Prof. Dr. Andrey E. Dorofeyev
National Medical University n.a. A.A.Bogomoletz
Chair of Internal Diseases#1
Shevchenko bul.17
01030 Kiev
Ukraine
dorofeyev@med.finfort.com

Dr. Pavel Drastich
Assoc. Prof. of Internal Medicine
Department of Hepatogastroenterology
Institute for Clinical and Experimental Medicine
14021 Prague
Czech Republic
drastich@hotmail.com

Dr. Dana Duricova
Clinical and Research Center for IBD
Iscare I.V.F. a.s., Lighthouse Jankovcova 1569/2c
170 04 Prague
Czech Republic
dana.duricova@seznam.cz

Prof. Dr. Marc Ferrante
Department of Gastroenterology
University Hospitals Leuven
KU Leuven
Herestraat 49
3000 Leuven
Belgium
marc.ferrante@uz.kuleuven.ac.be

Prof. Dr. Geoffrey M. Forbes
Department of Gastroenterology and Hepatology
Royal Perth Hospital
Box X2213 GPO
Perth, WA 6847
Australia
geoff.forbes@health.wa.gov.au

Dr. Marc Martí Gallostra
Consultant Colorectal Unit Digestive and General Surgery
Hospital Universitari Vall D’Hebron
Barcelona
Spain
marcmartig@gmail.com
Prof. Dr. Yves Panis
Service de Chirurgie Colorectale
Pôle des Maladies de l’Appareil Digestif (PMAD)
Hôpital Beaujon
100 bd du Gal Leclerc
92118 Clichy Cedex
France
yves.panis@bjn.aphp.fr

Dr. Marijana Protic
Assoc. Professor
Department of Gastroenterology and Hepatology
University Hospital Zvezdara
Dimitrija Tucovica 161
Belgrade
Serbia
marijana.n.protic@gmail.com

Prof. Dr. Walter Reinisch
Department of Medicine
Health Sciences Centre
McMaster University
1280 Main Street West
Hamilton, ON L8S 4K1
Canada
reinisw@mcmaster.ca

Florian Rieder, M.D.
Department of Gastroenterology and Hepatology
Lerner Research Institute
Cleveland Clinic Foundation
Cleveland, OH 44195
USA
riederf@ccf.org

Prof. Dr. Dr. Gerhard Rogler
Universitätsspital Zürich
Klinik für Gastroenterologie und Hepatologie
Rämistrasse 100
8091 Zürich
Switzerland
gerhard.rogler@usz.ch

Bruce E. Sands, M.D.
Professor of Medicine
Department of Gastroenterology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York NY 10029
USA
bruce.sands@mssm.edu

Prof. Dr. Jürgen Schölmerich
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60596 Frankfurt
Germany
aed@kgu.de

Dr. Zuzana Serclova
Surgical Department
University Hospital Bulovka
Prague
Czech Republic
sercl@seznam.cz

Prof. Dr. Eduard F. Stange
Gastroenterologie / Hepatologie
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Germany
eduard.stange@rbk.de

Prof. Dr. Helena Tlaskalová-Hogenová
Department of Immunology and Gnotobiology
Institute of Microbiology
Academy of Sciences of the Czech Republic
Prague
Czech Republic
tlaskalo@biomed.cas.cz

Dr. Zuzana Zelinkova
IBD Cetrum
5th Dept. of Internal Medicine
Tomasikova 50/C
831 04 Bratislava
Slovakia
zelinkova@assiduo.sk
Congress Office

During the Symposium 202

Hilton Prague
Pobrezni 1
18600 Prague 8
Czech Republic

Telephone: +49 (0)175/7795327

Opening Hours:
Thursday, April 28, 2016 16.00 – 21.00 h
Friday, April 29, 2016 7.00 – 17.30 h
Saturday, April 30, 2016 8.30 – 16.45 h

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Congress Report

The official congress report of the Symposium 202 “Evolving Therapies in Clinical Practice in IBD” will be published in English in the second half of 2016 by Karger, Switzerland. Orders for this book at a reduced subscription price of EUR 35,- can be placed at the Congress Office during the congress in Prague.

Congress Short Report

The congress short report of the Falk Symposium 202 “Evolving Therapies in Clinical Practice in IBD” will be published by the Falk Foundation e.V. with number FSR 202 in the second half of 2016.
Directions

congress venue

Hilton Prague Hotel

Main train station

Municipal House

Praha hl.n. (Autobusová St. Wilsonova)

Praha hlavní nádraží

station Hlavní nádraží

METRO

Státní opera

Muzeum - C

Muzeum - A

Vysoká škola ekonomická v Praze

Náměstí Republiky

Palladium

Městská národní banka

Pražská národní banka

Křižíková

Ke Štvanici

Florenc - C

Florenc - B

Na Poříči

Těšnový tunel

Vltava

Rohanské nábř.

Sokolovská

Kříží

prostřední

Poběžní

Sokolovská

Křižíková

Křižíková

Vltava

Pecová

Kollárová

Kolový

Kolový

Perlovka

Hybernská

Hybernská

Olšaděnka

Olšaděnka

Petrska

Soukenická

Trubářská

Zlatnická

Sadaba

Jindřichovská

Skolní

Sokolovská

Tvrdá

Hlavácká

Hlavácká

Zličín

Zličín

Sokolovská

Sokolovská

Sokolovská

Zličín

Zličín

Zličín

Zličín

Zličín

Zličín

Zličín

Zličín

Zličín

Zličín
General Information:

FALK FOUNDATION e.V.

Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Telephone: +49 (0) 761/15 14-125
Telefax: +49 (0) 761/15 14-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org